Meta AnalysisID 7640
胆碱酯酶抑制剂在帕金森病及相关疾病中的心血管结局：临床试验的系统评价与Meta分析
CRD42023485395
1. What are the cardiovascular outcomes of people with Parkinson’s disease and associated conditions when taking cholinesterase inhibitors? 2. How common are these events and what are the associated sequelae? 3. Are thes
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7640
- Evidence Id
- 16198
- Core Evidence Id
- 16198
- Source Meta Analysis Id
- 7634
- Herb2 Meta Analysis Id
- HBMA007634
- Crd Id
- CRD42023485395
- Title
- Cardiovascular outcomes of cholinesterase inhibitors in Parkinson’s disease and associated conditions: a systematic review and meta-analysis of clinical trials
- Review Question
- 1. What are the cardiovascular outcomes of people with Parkinson’s disease and associated conditions when taking cholinesterase inhibitors? 2. How common are these events and what are the associated sequelae? 3. Are these events more common in those on cholinesterase inhibitors versus placebo? 4. How do study teams monitor for cardiovascular adverse events in clinical trials of cholinesterase inhibitors?
- Study Type Included
- Inclusion: Randomised controlled trials, Randomised open-label trials, Randomised cross-over trials Exclusion: Systematic review, Case Studies, Conference abstracts, Protocols, Post-hoc Analysis, Pooled Analysis, Retrospective analysis, Longitudinal studies, Cross-sectional studies, Literature Reviews
- Condition Being Studied
- Cardiovascular outcomes in trials of cholinesterase inhibitors in people with Parkinson’s disease and other forms of Parkinsonism.
- Participant
- Any patient with one of the included conditions (Parkinsonism, Idiopathic Parkinson’s disease, parkinsonian disorders, Parkinson’s disease dementia, Lewy body dementia, Supranuclear Palsy, Multiple system atrophy, Corticobasal degeneration, atypical parkinsonism, Parkinson’s plus) were included in the review. There were no other restrictions on the participants.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion: Acetylcholinesterase Inhibitors, Cholinesterase Inhibitors, Rivastigmine, Donepezil, Galantamine, Exelon, Razadyne, Aricept, Evess Exclusion: Pyridostigmine Bromide, Neostigmine, Tacrine
- Comparator Control
- Inclusion: Placebo or other medication
- Main Outcome
- Incidence, classification and sequelae of CV AEs Cardiovascular adverse events occurring at any timepoint during trials of cholinesterase inhibitors in people with Parkinsons and related disorder. Cardiovascular adverse events will be defined using MedDRA coding as an event with a primary system organ class of either cardiac or vascular disorders. In situations where MedDRA classification was not used, CV AEs will be included and coded insofar as possible using the MedDRA classification. Synthesising data on incidence, classification and sequalae of cardiovascular events in this population will support clinicians in making informed decisions about prescribing in their clinical populations.
- Outcome Measure
- Additional Outcome
- To compare using meta-analysis (or meta-regression if appropriate), the incidence rates between cholinesterase treated groups and placebo-control groups. To describe the approach to managing risk and monitoring for cardiovascular adverse events in these studies including inclusion/exclusion criteria and study methodology including risk profiling and monitoring. This can be used to help stratify high risk patients with pre-existing cardiovascular co-morbidities and how to best manage them in conjunction with cholinesterase prescribing.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- Alice Harding [email protected]
- Organisational Affiliation
- Ageing & Movement Research Group (AMRG) Population Health Sciences, Bristol Medical School
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-11-21
- Registration Date
- 2023-11-29
- Anticipated Start Date
- 2023-09-04
- Anticipated Completion Date
- 2024-05-31
- Title Cn
- 胆碱酯酶抑制剂在帕金森病及相关疾病中的心血管结局：临床试验的系统评价与Meta分析
- Title En
- Cardiovascular outcomes of cholinesterase inhibitors in Parkinson’s disease and associated conditions: a systematic review and meta-analysis of clinical trials
- Bilingual Status
- complete